Innovent Biologics, Inc (IVBXF)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Innovent Biologics, Inc (IVBXF) is up 7.0% since the beginning of the year. At $10 per share, IVBXF is trading 31.0% below its 52-week high of $15. Investors who bought $1,000 worth of IVBXF shares 5 years ago would now be looking at an investment worth $869.

Innovent Biologics, Inc (IVBXF) has returned 6.96% so far this year and 33.59% over the past 12 months.

Based on dividend-adjusted daily data since Sep 4, 2019, IVBXF's average daily return is +0.18%, while the average monthly return is +2.86%. At this rate, an investment would double in approximately 2.0 years.

Historically, 50% of months were positive and 50% were negative. The best month was Dec 2020 with a return of +47.5%, while the worst month was Dec 2021 at -37.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.

On a daily basis, IVBXF closed higher 19% of trading days. The best single day was Oct 26, 2020 with a return of +53.3%, while the worst single day was Sep 9, 2021 at -40.0%.

Innovent Biologics, Inc has an annualized alpha of 55.84%, beta of 0.11, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 05, 2019.

• This stock captured 14.83% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -97.15%) - a profile typical of hedging or uncorrelated assets.
• Beta of 0.11 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

IVBXF ranks 59 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Innovent Biologics, Inc (IVBXF) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Innovent Biologics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Innovent Biologics, Inc was 82.96%, occurring on May 13, 2022. Recovery took 826 trading sessions.

The current Innovent Biologics, Inc drawdown is 24.23%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Innovent Biologics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Innovent Biologics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.